Aptima® BV &
CV/TV Assays

Accurate Results Optimize Care

Testing is critical for the correct treatment. While yeast infection or candida vaginitis (CV) is usually a result of overgrowth of Candida albicans, it can also be caused by the often azole-resistant strain Candida glabrata, which requires a different treatment pathway.1 Trichomoniasis (“Trich”), the most common curable STI, can contribute to more serious health outcomes if left untreated.1,2 Our assays detect the three most common causes of infectious vaginitis–bacterial vaginosis (BV), candida vaginitis (CV) and Trichomonas vaginalis (TV).3-7

30%

of symptomatic women will remain undiagnosed after clinical evaluation for vaginitis.8,9

90%

of vaginitis is caused by BV, CV and TV infections, either individually or in combination.5

21M

women in the US are impacted by bacterial vaginosis alone.1,10

Group office

Clear the Confusion Around Coinfection

Pathogen coinfection can occur frequently in women with vaginitis.11 The CDC recommends all women diagnosed with BV be tested for STIs.1

~36% of women with BV

were also infected with TV and/or Candida species12

Most conventional methods of diagnosis—including wet mount, microscopy, 
or laboratory examination—lack accuracy and are also not easily available.12,13 In contrast, NAAT molecular tests are highly sensitive, able to detect more 
co-infection cases than wet mount, culture, and Amsel’s criteria.12

Assays Designed for Maximum Performance

Aptima® BV Assay

Our assay was thoughtfully developed using insights from key opinion leaders, comprehensive literature review, extensive clinical studies and a robust clinical trial.6,12,14,15 Over 100 algorithms were evaluated to maximize sensitivity and specificity.16

Using a proprietary algorithm, the Aptima® BV Assay quantitatively detects these three target organisms. It then delivers a single, qualitative result for BV.6

Lactobacillus spp.
(L. gasseri, L. crispatus, L. jensenii)


G. vaginalis


A. vaginae

Multitest Swab

Aptima® CV/TV Assay

To help deliver clinically meaningful results, our assay detects and differentiates microorganisms associated with CV* and TV.7

Our Aptima® CV/TV Assay delivers three positive or negative results:7

Candida species group (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis)


Candida glabrata


Trichomonas vaginalis

*Although C. krusei can also be associated with azole resistance, this target was not included in our assay design due to its extremely low prevalence.17

DNA Probe Method is Less Comprehensive, Less Sensitive and Lacks Specificity

BV CV TV Table

Let’s Connect

Have a question or need to talk to a Hologic team member? We’re here to help.

1. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1.

2. Thomason J, et al. Trichomonas vaginalis. Obst Gynecol. 1989;74(3)2:536-541.

3. Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol. 1991;165(Part 2): 1168-76.

4. ACOG Vaginitis Frequently Asked Questions. Accessed December 3, 2025. https://www.acog.org/womens-health/faqs/vaginitis.

5. Paladine HL. Vaginitis: Diagnosis and Treatment. Am Fam Physician. 2018 Mar 1;97(5):321-329.

6. Aptima BV Assay. US package insert AW-31481-001. Hologic, Inc.; 2025.

7. Aptima CV/TV Assay, Pather. US package insert AW-31482-001. Hologic, Inc.; 2025.

8. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA .2004;291(11):1368–1379. doi:10.1001/jama.291.11.1368.

9. Hainer BL, Gibson MV. Vaginitis. Am Fam Physician. 2011 Apr 1;83(7):807-15. PMID: 21524046.

10. Koumans EH. The Prevalence of Bacterial Vaginosis in the United States, 2001-2004; Associations with Symptoms, Sexual Behaviors, and Reproductive Health.

11. Schwebke JR, Nyirjesy P, Dsouza M, Getman D. Vaginitis and risk of sexually transmitted infections: results of a multi-center U.S. clinical study using STI nucleic acid amplification testing. J Clin Microbiol. 2024 Sep 11;62(9):e0081624. doi: 10.1128/jcm.00816-24.

12. Schwebke JR, Taylor SN, Ackerman R, et al. Clinical Validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: Results from a Prospective Multicenter Clinical Study. J Clin Microbiol. 2020;58(2):e01643-19. Published 2020 Jan 28. doi:10.1128/JCM.01643-19.

13. Nye M, et al. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol. 2009;200(2):188.e1-7.

14. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol. 2007;45(10):3270-3276. doi:10.1128/JCM.01272-07. 2.

15. Coleman JS, Gaydos CA. Molecular Diagnosis of Bacterial Vaginosis: An Update. J Clin Microbio. 2018 Aug27; 56(9):e00342-18. doi:10.1128/JCM.00342-18 Microbiology 46(4):1501-1503.

16. Hologic, Inc. Data on File.

17. Paradis S, Yu J, Lejeune M. Elevating the Standard of Care for Women’s Health : The BD MAX TM Vaginal Panel and Management of Vaginal Infections of women experience. Published 2017. Accessed November 12, 2025. https://www.semanticscholar.org/paper/Elevating-the-Standard-of-Care-for-Women-%E2%80%99-s-Health-Paradis-Yu/f383947aa788784c3097d7a100e5e068b1960d84.

18. Committee on Practice Bulletins—Gynecology. Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. Obstet Gynecol. 2020;135(1):e1-e17.

19. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23(2):253-273. doi:10.1128/CMR.00076-09.

20. Cartwright, Charles P, Ramachandran, et al. Comparison of nucleic acid amplification assays with BD affirm VPIII for diagnosis of vaginitis in symptomatic women. J Clin Microbiol. 2013;51(11): 3694-3699.

21. Redelinghuys MJ, Geldenhuys J, Jung H, Kock MM. Bacterial vaginosis: current diagnostic avenues and future opportunities. Front Cell Infect Microbiol. 2020;10:354.